2nd Gene Therapy Potency Assay Summit Returns to Boston!
R&D
According to the FDA, 2024 will be the ’breakout year’ for gene therapies. For these therapies to gain regulatory approval, it's crucial to have robust potency assays in place, making it paramount that an effective potency design is incorporated into every drug developer’s analytical strategy.
As gene therapy biopharma continues to try to link an often-unclear mechanism of action to potency, increasing regulatory scrutiny means potency data packages must be more robust than ever before.
Join your peers this July to:
- Navigate the new FDA gene therapy potency guidelines
- Discover how potency assay development for novel delivery modalities
- Develop protocols to optimize your resource management
- Enhance your assay precision with emerging technologies
Secure your place here or get in touch with the team – info@hansonwade.com
